Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal contraception.

G W Creasy1, L S Abrams, A C Fisher

  • 1The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA.

Seminars in Reproductive Medicine
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tapping into cyanobacteria electron transfer for higher exoelectrogenic activity by imposing iron limited growth.

RSC advances·2022
Same author

A Markov Multi-State model of lupus nephritis urine biomarker panel dynamics in children: Predicting changes in disease activity.

Clinical immunology (Orlando, Fla.)·2018
Same author

A Note on the Pathology of Erythema Nodosum.

Bristol medico-chirurgical journal (1883)·2017
Same author

Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2016
Same author

Adherence to Sports-Injury Rehabilitation Programs.

The Physician and sportsmedicine·2016
Same author

Impact on hepatic estrogen-sensitive proteins by a 1-year contraceptive vaginal ring delivering Nestorone® and ethinyl estradiol.

Contraception·2015
Same journal

Understanding PGT-M: A Guide for Clinicians.

Seminars in reproductive medicine·2026
Same journal

Genetics in Reproduction.

Seminars in reproductive medicine·2026
Same journal

Genetics in Reproduction.

Seminars in reproductive medicine·2026
Same journal

Clinical Genetics in Reproductive Medicine: Variant Classification, Medically Actionable Genes, and Carrier Screening.

Seminars in reproductive medicine·2026
Same journal

Clinical Testing for Genetic Conditions.

Seminars in reproductive medicine·2026
Same journal

Genetics of Primary Ovarian Insufficiency.

Seminars in reproductive medicine·2026
See all related articles

The weekly contraceptive patch delivers norelgestromin and ethinyl estradiol, offering ovulation suppression and cycle control comparable to oral contraceptives. This non-invasive birth control method demonstrated high adherence rates and a favorable safety profile.

Area of Science:

  • Reproductive Health
  • Contraception
  • Pharmacology

Background:

  • Review of clinical studies on the Ortho Evra/Evra contraceptive patch.
  • The patch delivers 150 microg norelgestromin (NGMN) and 20 microg ethinyl estradiol (EE) daily.
  • Comparison with various oral contraceptive formulations.

Purpose of the Study:

  • To summarize clinical data on the efficacy, cycle control, and safety of the weekly contraceptive patch.
  • To compare the patch's performance against established oral contraceptives.
  • To evaluate user adherence and adverse events.

Main Methods:

  • Clinical study review.
  • Analysis of ovulation suppression, cycle control, and cervical mucus changes.
  • Assessment of contraceptive efficacy and safety compared to oral contraceptives (norgestimate, levonorgestrel, desogestrel).

Related Experiment Videos

Main Results:

  • The patch demonstrated ovulation suppression and cycle control similar to oral norgestimate/EE.
  • It significantly decreased mean maximum follicular diameter compared to certain oral levonorgestrel formulations.
  • Efficacy, cycle control, and safety were comparable to oral contraceptives, with significantly higher adherence to the weekly regimen versus daily oral dosing.

Conclusions:

  • The contraceptive patch is an effective, non-invasive, weekly birth control option.
  • It offers comparable efficacy and safety to oral contraceptives with improved user adherence.
  • The patch represents a valuable addition to available contraceptive methods.